Top 10 ASX Dividend Stocks for Nov 2026 Download Free Report

1800-272-662
Shopping Cart 0
countryflagAU
Login

Home CompaniesPharmAust Ltd

PharmAust Ltd

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
None AUD 0.00(0%)
Last update at 2025-02-27T06:20:47.383337Z
Market Cap
111.93M

Momentum Score

…

PharmAust Limited, a clinical stage biotechnology company, develops therapeutics for neurodegenerative diseases in Switzerland, Australia, the United States, and internationally. The company develops drug discovery intellectual property for the treatment of various cancers and neurological diseases. Its lead candidate is Monepantel (MPL), a small molecule drug which is in Phase II clinical trials for the treatment of amyotrophic lateral sclerosis, as well as to treat other neurodegenerative diseases, such as Alzheimer's and Parkinson's disease. PharmAust Limited was incorporated in 2000 and is based in Melbourne, Australia.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

52 Week Price Range
0.15
Low
0.43
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High

Key Metrics*

Previous Close
-
Dividend Yield
-
Revenue TTM
0.84M
Revenue Per Share
0.00
Gross Profit TTM
2.48M
Debt / Equity
0.27
ROE
-126.09%
Net Debt
-9.71M
ROCE
-25.65%
Diluted EPS TTM
-0.02

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Type yearly yearly yearly yearly yearly
Date 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Income before tax -6.21M -1.71M -1.34M -1.36M -1.62M
Net income -6.21M -1.71M -1.34M -1.36M -1.66M
Selling general administrative 4.30M 4.74M 3.85M 4.24M 4.39M
Gross profit 2.04M 3.07M 1.92M 2.95M 3.34M
Reconciled depreciation 0.33M 0.31M 0.30M 0.27M 0.17M
Ebit -2.62M -1.62M -1.26M -1.24M -1.57M
Ebitda -2.30M -1.30M -0.96M -0.97M -1.40M
Depreciation and amortization 0.33M 0.31M 0.30M 0.27M 0.17M
Operating income -3.25M -1.62M -1.27M -1.25M -1.57M
Other operating expenses -7.36M -5.50M -4.48M -4.87M 5.93M
Interest expense 0.08M 0.09M 0.08M 0.12M 0.05M
Tax provision 0.00M 0.00M 0.00M 0.00M 0.00M
Interest income 0.08M 0.00M 0.01M 0.12M 0.05M
Net interest income -0.00M -0.09M -0.06M -0.12M -0.03M
Income tax expense 1.08M 1.22M 1.60M 1.05M 0.05M
Total revenue 2.82M 3.38M 2.14M 3.20M 3.67M
Total operating expenses 5.74M 5.82M 4.71M 5.12M 5.60M
Cost of revenue 0.79M 0.31M 0.23M 0.25M 0.33M
Total other income expense net -2.51M 1.13M 1.52M 0.93M -0.05M
Net income from continuing ops -6.21M -1.71M -1.34M -1.36M -1.55M
Net income applicable to common shares -6.21M -1.71M -1.34M -1.36M -1.55M
Breakdown 2024-06-30 2023-06-30 2022-06-30 2021-06-30 2020-06-30
Type yearly yearly yearly yearly yearly
Date 2024-06-30 2023-06-30 2022-06-30 2021-06-30 2020-06-30
Total assets 11.12M 6.13M 10.08M 10.95M 10.75M
Intangible assets - 3.11M 3.11M 3.14M 3.11M
Other current assets 1.26M 0.08M 0.02M 0.02M 0.03M
Total liab 0.90M 2.24M 2.23M 2.07M 2.22M
Total stockholder equity 10.23M 3.89M 7.84M 8.88M 8.53M
Other current liab 0.07M 0.42M 0.56M 0.35M 0.50M
Common stock 69.94M 57.63M 55.34M 55.33M 53.77M
Capital stock 69.94M 57.63M 55.34M 55.33M 53.77M
Retained earnings -64.13M -56.46M -50.25M -48.54M -47.20M
Other liab - 0.00M 0.03M 0.03M 0.04M
Other assets - 0.32M - - -
Cash 9.71M 2.71M 2.42M 3.02M 2.88M
Total current liabilities 0.90M 1.35M 1.17M 0.91M 1.10M
Current deferred revenue - -0.16M -0.35M -0.15M -0.31M
Net debt -9.71M -1.66M -1.03M -1.74M -1.41M
Short term debt - 0.16M 0.35M 0.15M 0.35M
Short long term debt - - 0.21M 0.04M 0.18M
Short long term debt total - 1.05M 1.39M 1.28M 1.47M
Other stockholder equity - -1.17M -5.10M -6.79M -6.57M
Property plant equipment - 0.00M 3.24M 3.45M 3.57M
Total current assets 11.12M 3.02M 3.73M 4.36M 4.07M
Net tangible assets - 0.78M 4.73M 5.74M 5.42M
Short term investments 0.00M 0.02M 0.00M 0.00M 0.00M
Net receivables 0.15M 0.15M 0.19M 0.24M 0.30M
Long term debt - - - 0.00M 0.04M
Inventory - 0.09M 1.04M 1.01M 0.86M
Accounts payable 0.83M 0.93M 0.60M 0.56M 0.56M
Accumulated other comprehensive income 4.42M 2.72M 2.75M 2.09M 1.96M
Common stock total equity - - - - 53.77M
Non currrent assets other - -3.11M -6.35M -6.60M -6.68M
Non current assets total 0.00M 3.11M 6.35M 6.60M 6.68M
Capital lease obligations - 1.05M 1.17M 1.24M 1.25M
Long term debt total - 0.89M 1.04M 1.13M 1.12M
Breakdown 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Type yearly yearly yearly yearly yearly
Date 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Investments -0.03M -0.04M -0.14M -0.03M -0.15M
Change to liabilities 0.32M 0.04M 0.00M -0.12M 0.06M
Total cashflows from investing activities -0.03M -0.04M -0.14M -0.03M -0.15M
Net borrowings -0.35M 0.05M -0.32M -0.29M -0.10M
Total cash from financing activities 1.89M 0.77M 1.22M 2.09M 1.92M
Change to operating activities -0.04M 0.01M -0.01M 0.07M -0.04M
Net income -6.21M -1.71M -1.34M -1.36M -1.66M
Change in cash 0.29M -0.60M 0.14M 0.79M 0.22M
Begin period cash flow 2.42M 3.02M 2.88M 2.09M 1.88M
End period cash flow 2.71M 2.42M 3.02M 2.88M 2.09M
Total cash from operating activities -1.56M -1.33M -0.94M -1.27M -1.55M
Issuance of capital stock 2.24M 0.72M 1.54M 2.38M 2.02M
Depreciation 0.33M 0.31M 0.30M 0.27M 0.17M
Other cashflows from investing activities -0.00M 0.00M -0.04M - -
Change to inventory -0.00M -0.03M -0.15M -0.25M -0.04M
Change to account receivables -0.04M 0.06M 0.06M -0.04M -0.01M
Sale purchase of stock 2.24M 0.72M 1.54M 2.38M 2.02M
Other cashflows from financing activities -0.03M 0.21M -0.14M -0.03M -0.15M
Change to netincome 4.08M -0.01M 0.20M 0.14M -0.14M
Capital expenditures 0.03M 0.04M 0.14M 0.03M 0.15M
Change in working capital -0.05M 0.02M -0.09M -0.28M 0.69M
Stock based compensation -0.01M -0.05M 0.16M 0.05M -
Other non cash items 4.32M 0.06M 0.10M -0.18M 1.38M
Free cash flow -1.60M -1.38M -1.08M -1.30M -0.15M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(AUD)
Price
(AUD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
CSL
CSL Ltd		 2.86
1.42%		 204.54 - 22.57 6.15 4.48 4.82 10.06
TLX
TELIX Pharmaceuticals Ltd		 -0.32
2.28%		 13.70 93.87 166.67 5.37 6.37 3.85 47.29
NEU
Neuren Pharmaceuticals Ltd		 -0.30
1.25%		 23.66 154.93 36.36 42.38 7.52 31.95 160.40
MSB
Mesoblast Ltd		 -0.07
3.69%		 1.96 - 454.55 23.43 3.36 18.28 -9.86

Profile*

PharmAust Ltd

PharmAust Limited, a clinical stage biotechnology company, develops therapeutics for neurodegenerative diseases in Switzerland, Australia, the United States, and internationally. The company develops drug discovery intellectual property for the treatment of various cancers and neurological diseases. Its lead candidate is Monepantel (MPL), a small molecule drug which is in Phase II clinical trials for the treatment of amyotrophic lateral sclerosis, as well as to treat other neurodegenerative diseases, such as Alzheimer's and Parkinson's disease. PharmAust Limited was incorporated in 2000 and is based in Melbourne, Australia.

96-100 Albert Road, Melbourne, VIC, Australia, 3205

61 3 9692 7222

https://www.pharmaust.com

Name Title Year Born
Dr. Roger Aston B.Sc., BSc (Hons), Ph.D. Exec. Chairman & Acting CEO 1956
Mr. Sam Michael Wright A.C.I.S., ACIS, AFin, DipAcc, M.A.I.C.D., MAICD Fin. Director, Company Sec. & Non-Exec. Director 1978
Mr. Robert Charles Bishop LLB (Hons) Exec. Director NA
Ms. Fiona Milner Gen. Mang. of Epichem Pty Ltd NA
Dr. Gary Pitt Head of Chemistry NA
Dr. James Rixson Head of Production NA
Mr. Sam Michael Wright A.C.I.S., ACIS, AFin, DipAcc, M.A.I.C.D., MAICD Finance Director, Company Secretary & Non-Executive Director 1978
Mr. Robert Charles Bishop LLB (Hons) Executive Director NA
Ms. Fiona Milner General Manager of Epichem Pty Ltd NA
Dr. Michael Thurn Ph.D. CEO & Director NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

CU6
AUD 2.05
+23.49%
DMP
AUD 25.06
+12.93%
G6M
AUD 2.74
+10.93%
XRO
AUD 75.17
+6.08%
SGR
AUD 0.17
+6.06%
AXQ
AUD 3.07
-18.35%
BOE
AUD 1.50
-9.39%
GQG
AUD 0.71
-8.97%
MI6
AUD 0.81
-8.52%
ELV
AUD 3.73
-8.35%

Equity Sectors*

  • Basic Materials

    -3.09%

  • Communication Services

    +0.75%

  • Consumer Cyclical

    +0.43%

  • Consumer Defensive

    +0.12%

  • Energy

    -1.07%

  • Financial Services

    -0.02%

  • Healthcare

    +1.08%

  • Industrials

    -0.22%

  • Real Estate

    +0.61%

  • Technology

    -1.69%

  • Utilities

    -0.18%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…